Zi Bo Dong

Corporate Officer/Principal presso Jumpcan Pharmaceutical Co. Ltd.

54 anni

Health Technology

Profilo

Zi Bo Dong is currently the Deputy GM & Head of Drug Research Institute at Jumpcan Pharmaceutical Co. Ltd.
Prior to this, he worked as the Director & Deputy General Manager at Hubei Jumpcan Pharmaceutical Co., Ltd.

Posizioni attive di Zi Bo Dong

Società	Posizione	Inizio
Jumpcan Pharmaceutical Co. Ltd. Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million.	Corporate Officer/Principal	-

Tutte le posizioni attive di Zi Bo Dong

Precedenti posizioni note di Zi Bo Dong

Società	Posizione	Fine
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	Direttore/Membro del Consiglio	28/07/2018

Vedi nel dettaglio l'esperienza di Zi Bo Dong

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Zi Bo Dong

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	Health Technology

Aziende private	1
Jumpcan Pharmaceutical Co. Ltd. Jumpcan Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Hubei Jumpcan Pharmaceutical Co., Ltd., Jumpcan Pharmaceutical Co. Ltd. is a pharmaceutical company based in Taixing, China. The Chinese company offers a range of products including mouthwash, cough medicine, and pain relief ointments. The CEO of the company is Long Xiang Cao. Jumpcan Pharmaceutical Co. was acquired by Hubei Jumpcan Pharmaceutical Co., Ltd. from Jiangsu Jichuan Holdings Group Co. Ltd. on December 20, 2013 for $911.88 million.	Health Technology